Results 41 to 50 of about 636,170 (221)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase

Royal Society Open Science, 2021
Bruton's tyrosine kinase (BTK) plays a vital role in mature B-cell proliferation, development and function. Its inhibitors have gradually been applied for the treatment of many B-cell malignancies. However, because of treatment-associated drug resistance
Simei Qiu, Yunfeng Liu, Quhuan Li
doaj   +1 more source

Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach? [PDF]

Ther Adv Hematol
Waldenström macroglobulinemia is an indolent B-cell lymphoma which although remains incurable, there are a lot of treatment options. Today, Bruton tyrosine kinase inhibitors have a central role in the management of the disease either as monotherapy or ...
Solia E, Kastritis E.
europepmc   +3 more sources

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations

Therapeutic Advances in Hematology, 2022
Bruton’s tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL).
Alexandra R. Lovell, Nadya Jammal, Prithviraj Bose   +2 more
doaj   +1 more source

B Cells are Activated via a Nanoporous Interface that Stabilizes Microvilli and Engages Mechanosensitive Ion Channels

Advanced Science, EarlyView.
B cells can be activated independently of antigen recognition via mechanical stimulation through nanoporous substrates. Exposure to such substrates induced B cell microvilli extension into the pores, intracellular Ca2+ signaling, phosphorylation of signaling proteins, and CD69 expression.
Nozie D. Aghaizu, Willi Weber, Nadine Strempel, Asya Polat, Enrico Klotzsch   +4 more
wiley   +1 more source

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance

Blood and Lymphatic Cancer: Targets and Therapy, 2022
Frédérique St-Pierre,1 Shuo Ma1,2 1Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; 2Department of Medicine, Division of Hematology/Oncology, Feinberg ...
St-Pierre F, Ma S
doaj  

Upadacitinib Restrains the Pathogenic Fitness of CD4+ T Cells and Aberrant B Cell Programming in Optic Neuritis

Advanced Science, EarlyView.
Single‐cell profiling and functional perturbation reveal coordinated JAK1‐pSTAT3 downstream programs in optic neuritis, including MCL1‐dependent fitness of pathogenic CD4+ Tem cells and glycolysis‐linked, cholesterol‐sensitive B‐cell responses associated with RORA. Upadacitinib disrupts this reciprocal T‐B‐cell circuit and alleviates neuroinflammation,
Gengchen Jiang, Qi Jiang, Lian Han, Yue Peng, Xingyu Liu, Tong Yang, Hao Huang, Jiaying Liu, Yuan Gao, Hui Yang, Wenjun Zou, Zhaohuai Li, Wenru Su   +12 more
wiley   +1 more source

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies

CPT: Pharmacometrics & Systems Pharmacology
The effectiveness of Bruton tyrosine kinase (BTK) inhibitors is influenced by the level of BTK occupancy in target tissues. In randomized phase 3 studies, progression‐free survival (PFS) with zanubrutinib was superior to ibrutinib, whereas acalabrutinib ...
Oleg Demin Jr, Ying Ou, Galina Kolesova, Dmitry Shchelokov, Alexander Stepanov, Veronika Musatova, Sri Sahasranaman, Yating Zhao, Xiangyu Liu, Zhiyu Tang, William D. Hanley   +10 more
doaj   +1 more source

Single‐Cell Transcriptomic Profiling Identifies B Cell‐Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia

Advanced Science, EarlyView.
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo, Yanxia Zhan, Lili Ji, Pengcheng Xu, Pu Chen, Hao Pang, Yunan Ling, Fanli Hua, Xibing Zhuang, Hao Chen, Yunfeng Cheng   +10 more
wiley   +1 more source

Emerging therapy targeting tyrosine-protein kinase BTK: potential for ibrutinib and other BTK inhibitors

, 2013
Tyrosine-protein kinase BTK (Bruton tyrosine kinase) plays a critical role in the B cell receptor signaling pathway, and as such, mediates many immune responses.
S.A. Rushworth, D.J. MacEwan, Bowles, Kristian, K.M. Bowles, Rushworth, Stuart, MacEwan, David   +5 more
core   +1 more source

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

Therapeutic Advances in Neurological Disorders
Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Laura Airas, Robert A. Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J. Williams, Bernd C. Kieseier, Heinz Wiendl   +8 more
doaj   +1 more source